denali
therapeutics
announces
closing
collaboration
share
purchase
agreements
biogen
nasdaq
dnli
south
san
francisco
globe
newswire
denali
therapeutics
nasdaq
dnli
biopharmaceutical
company
developing
broad
portfolio
product
candidates
engineered
cross
barrier
bbb
neurodegenerative
diseases
today
announced
signing
definitive
collaboration
license
agreement
right
first
negotiation
option
license
agreement
biogen
connection
previously
announced
binding
provisional
collaboration
license
agreement
neurodegenerative
diseases
biogen
closing
related
common
stock
purchase
agreement
connection
signing
agreements
biogen
denali
receive
million
upfront
payment
addition
september
private
placement
transaction
biogen
made
equity
investment
million
denali
purchase
newly
issued
shares
denali
common
stock
approximately
per
share
connection
previously
announced
stock
purchase
agreement
terms
definitive
collaboration
license
agreement
companies
denali
small
molecule
inhibitors
repeat
kinase
parkinson
disease
denali
products
united
states
china
shared
responsibility
worldwide
development
costs
percent
biogen
percent
denali
well
profits
losses
commercialization
united
states
percent
biogen
percent
denali
china
percent
biogen
percent
denali
outside
united
states
china
biogen
responsible
commercialization
pay
denali
tiered
royalties
program
achieve
certain
development
commercial
milestones
denali
eligible
receive
billion
potential
milestone
payments
mutations
cause
parkinson
disease
regulator
lysosomal
function
impaired
parkinson
disease
may
contribute
neurodegeneration
previously
announced
denali
small
molecule
inhibitor
selected
progress
clinical
studies
expected
commence
terms
right
first
negotiation
option
license
agreement
biogen
biogen
exclusive
option
rights
two
programs
neurodegenerative
diseases
using
denali
transport
vehicle
tv
technology
platform
including
amyloid
beta
plus
right
first
negotiation
two
additional
unnamed
tv
platform
programs
denali
decide
seek
collaboration
programs
rights
limited
certain
modalities
indications
also
exercisable
limited
time
period
denali
proprietary
tv
technology
designed
effectively
deliver
large
therapeutic
molecules
antibodies
enzymes
proteins
oligonucleotides
across
bbb
intravenous
administration
closing
common
stock
purchase
agreement
definitive
collaboration
agreements
subject
satisfaction
customary
closing
conditions
including
expiration
waiting
period
hsr
antitrust
improvements
act
additional
details
regarding
financial
terms
found
denali
form
filed
securities
exchange
commission
october
denali
program
small
molecule
inhibitor
invented
denali
completed
dosing
healthy
volunteers
ongoing
phase
clinical
study
completed
dosing
parkinson
patients
phase
clinical
study
denali
currently
completing
dose
escalation
cohorts
expanded
phase
additional
cohort
phase
study
define
full
therapeutic
window
molecule
based
clinical
data
date
generated
europe
appears
acceptable
safety
tolerability
profile
met
desired
target
engagement
goals
investigational
new
drug
application
cleared
food
drug
administration
july
enables
expansion
denali
clinical
trials
globally
denali
therapeutics
denali
therapeutics
biopharmaceutical
company
developing
broad
portfolio
product
candidates
engineered
cross
barrier
bbb
neurodegenerative
diseases
denali
pursues
new
treatments
rigorously
assessing
genetically
validated
targets
engineering
delivery
across
bbb
guiding
development
biomarkers
demonstrate
target
pathway
engagement
denali
based
south
san
francisco
additional
information
please
visit
cautionary
note
regarding
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
expressed
implied
press
release
include
limited
plans
timelines
expectations
related
inhibitor
molecules
denali
tv
technology
platform
tv
programs
inhibitors
modifying
therapy
parkinson
disease
ability
tv
technology
effectively
deliver
large
therapeutic
molecules
across
bbb
expectations
regarding
collaboration
biogen
including
financial
aspects
collaboration
potential
benefits
results
transaction
biogen
expectations
regarding
commencement
clinical
trials
expectations
regarding
ongoing
clinical
trials
plans
conduct
development
commercialization
activities
actual
results
subject
risks
uncertainties
may
differ
materially
indicated
statements
result
risks
uncertainties
including
limited
risks
denali
business
operations
caused
directly
indirectly
evolving
pandemic
risk
occurrence
event
change
circumstance
could
give
rise
termination
agreements
biogen
risks
related
effect
announcement
transaction
denali
business
relationships
operating
results
stock
price
business
generally
denali
early
stages
clinical
drug
development
denali
partners
ability
complete
development
approved
commercialization
product
candidates
denali
partners
ability
enroll
patients
clinical
trials
denali
reliance
third
parties
manufacture
supply
product
candidates
clinical
trials
denali
dependence
successful
development
bbb
platform
technology
whether
platform
technology
effectively
delivers
large
therapeutic
molecules
across
bbb
denali
partners
ability
conduct
complete
clinical
trials
expected
timelines
risk
preclinical
profiles
results
early
clinical
trials
denali
product
candidates
may
translate
later
clinical
trials
risk
denali
inhibitors
may
sufficiently
modify
parkinson
disease
uncertainty
product
candidates
receive
regulatory
approval
necessary
commercialized
denali
ability
continue
create
pipeline
product
candidates
develop
commercially
successful
products
developments
relating
denali
competitors
industry
including
competing
product
candidates
therapies
denali
ability
obtain
maintain
protect
intellectual
property
rights
related
product
candidates
implementation
denali
strategic
plans
business
product
candidates
bbb
platform
technology
denali
ability
obtain
additional
capital
finance
operations
needed
denali
ability
accurately
forecast
future
financial
results
current
environment
general
economic
market
conditions
risks
uncertainties
including
described
denali
recent
annual
report
form
recent
quarterly
report
form
denali
future
reports
filed
sec
statements
press
release
based
information
available
denali
date
hereof
denali
disclaims
obligation
update
statements
except
required
law
investor
relations
contact
laura
hansen
vice
president
investor
relations
hansen
media
contacts
lizzie
hyland
lhyland
morgan
warners
mwarners
